Tempus AI and Butterfly Network both reported their Q2 2025 results, highlighting AI-driven trajectories. Tempus AI showed rapid top-line expansion and progress towards profitability, while Butterfly Network reported modest revenue growth and efforts to scale adoption of its AI-driven ultrasound platform. Investors face a choice between high-growth precision medicine and a turnaround-stage imaging platform.

Shares of Tempus AI surged 29.9% in the past month, while Butterfly Network stock declined by 21.6%. Butterfly’s moderate revenue gains and cash burn led to investor caution. The Medical Info Systems industry rose by 2.7%, and the S&P 500 index by 1.5% in the same period.

Tempus AI demonstrated strong Q2 2025 results, with revenues up 90% YoY and an adjusted gross margin of 62%. The company is innovating with new products like xM liquid biopsy and expanding its data ecosystem. Butterfly Network is gaining enterprise momentum with large-scale deployments and transitioning to a software-driven model with Compass AI.

Analysts suggest a better upside for Butterfly Network, with a 128% increase in the average price target. Meanwhile, Tempus AI’s average price target represents an 8.1% decline. Investors may find Butterfly Network more compelling in the near term due to its turnaround potential and attractive valuation compared to Tempus AI.

Zacks Investment Research highlights five stocks set to double, offering opportunities for significant growth in the coming year. The report features handpicked stocks with the potential to gain over 100%. These stocks are flying under Wall Street radar, providing early investment opportunities for investors looking for high returns.

Read more at Nasdaq: Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?